Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40804 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL190173 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL2896341 | 0.95 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL1991179 | 0.95 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL1991177 | 0.95 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL14398395 | 0.94 | HPGD (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL25980668 | 0.94 | HPGD (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL31336384 | 0.94 | HPGD (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL9381153 | 0.90 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL2030521 | 0.90 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2ALDH1A1HPGDCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974842-A | Preparation method of pyrroltinib | 苏州宝圣医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115073344-A | Preparation method and application of R- (1-tert-butyloxycarbonyl-pyrrolidine-2-yl) acrylic acid | 苏州富士莱医药股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| EP-1021424-B1 | THIADIAZOLE AMIDE MMP INHIBITORS | UPJOHN CO (US) | 2003-02-26 | — | — | EP | claimed |
| EP-0973517-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | claimed |
| US-6288105-B1 | COMPOUNDS SUCH AS (S)-2-(4-((2-AMINO-3-HYDROXY-1-OXOPROPYL)AMINO)PHENYL)-6-HYDRO XY-3-(3-METHOXY-4-(1-PYRROLIDINYLMETHYL)BENZYL)BENZO(B)THIOPHE NE | ELI LILLY AND COMPANY | 2001-09-11 | — | — | US | claimed |
| EP-0973517-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998048794-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | claimed |
| US-4760061-A | Antioestrogenic agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-26 | — | — | US | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731631-A1 | BENZAMIDAZOLE DIAZAPINONE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-1990004588-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-05-03 | — | — | WO | disclosed |
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4760061-A | Antioestrogenic agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-26 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0160508-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HSD17B10 1332/4885SMN1; SMN2 4141/4885ALDH1A1 1299/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | HSD17B10 1259/4885SMN1; SMN2 3226/4885ALDH1A1 3723/4885 |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | MLLT3, MLLT1, FLT3 | HSD17B10 2268/4885SMN1; SMN2 4179/4885ALDH1A1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.